Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2002-07-24
2009-11-24
O Hara, Eileen B (Department: 1638)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S069100, C435S320100, C435S456000, C536S023100, C536S023400, C536S023720, C536S024100
Reexamination Certificate
active
07622300
ABSTRACT:
Trans-lentiviral gene transfer vectors, vector systems, vector particles, and methods for transduction of primary nondividing cells using the same, are described. Further described are modifications to the gene transfer vectors that improve transduction efficiency and/or gene expression, e.g., by incorporating the cis-acting sequences, PPT-CTS and/or WPRE, and derivatives or analogs thereof.
REFERENCES:
patent: 5175099 (1992-12-01), Willis
patent: 5378806 (1995-01-01), Willis
patent: 5665577 (1997-09-01), Sodroski et al.
patent: 5861161 (1999-01-01), Cohen et al.
patent: 5981276 (1999-11-01), Sodroski et al.
patent: 6043081 (2000-03-01), Cohen et al.
patent: 6365150 (2002-04-01), Leboulch et al.
patent: 6602705 (2003-08-01), Barnett et al.
patent: 275259 (1990-01-01), None
patent: 356021 (1990-02-01), None
patent: WO 90/15875 (1990-12-01), None
patent: WO 92/00987 (1992-01-01), None
patent: WO 93/24632 (1993-12-01), None
patent: WO 93/25235 (1993-12-01), None
patent: WO 94/17825 (1994-08-01), None
patent: WO 95/16705 (1995-06-01), None
patent: WO 95/26361 (1995-10-01), None
patent: WO 96/07741 (1996-03-01), None
patent: WO 96/11696 (1996-04-01), None
patent: WO 96/32494 (1996-10-01), None
patent: WO 97/36481 (1997-10-01), None
patent: WO 99/51754 (1999-10-01), None
patent: WO 99/58701 (1999-11-01), None
patent: WO 00/39302 (2000-07-01), None
Banerjee et al., Biochimica et Biophysica Acta, 2000, vol. 1480, pp. 1-5.
Groth et al., J. Mol. Biol., 2004, vol. 335, pp. 667-678.
Daboussi, Genetica, 1997, vol. 100, pp. 253-260.
Bennett, Journal of Antimicrobial Chemotherapy, 1999, vol. 43, pp. 1-4.
Kempkin et al., BioEssays, 1998, vol. 20, pp. 652-659.
Zhu et al., J. Virol., 2004, vol. 78, No. 10, pp. 5045-5055.
Akari, et al., “Biological Characterization Of Human Immunodeficiency Virus Type 1 and 2 Mutants In Human Perizheral Blood Mononuclear Cells,”Arch. Virol., 1992, pp. 157-167, vol. 123.
Akkina, et al. “High-Efficiency Gene Transfer into CD34+Cells with a Human Immunodeficiency Virus Type 1-Based Retroviral Vector Pseudotyped with Vesicular Stomatitis Virus Envelope Glycoprotein G,”J. Virol., 1996, pp. 2581-2585, vol. 70.
Alton, et al., “Nucleotide Sequence Analysis of the Chloramphenicol Resistance Transposon Tn9,”Nature, 1979, pp. 282:864-869, vol. 282.
Amado, et al., “Lentiviral Vectors—the Promise of Gene Therapy within Reach?,”Science, 1999, pp. 674-676, vol. 285.
Ansari-Lari, et al., “Expression of Human Immunodeficiency Virus Type I Reverse Transcriptase in Trans During Virion Release and after Infection,”J. Virol., 1996, pp. 3870-3875, vol. 70.
Ansari-Lari, et al., “Analysis of Human Immunodeficiency Virus Type I Integrase Mutants,”Virology, 1995, pp. 332-335, vol. 70.
Balotta, et al., “Antisense Phosphorothioate Oligodeoxynucleotides Targeted to the vpr Gene Inhibit Human Immunodeficiency Virus Type I Replication in Primary Human Macrophages,”J. Virol., 1993,.pp. 4409-4404, vol. 67.
Bukovsky, et al., “Lack of Integrase Can Markedly Affect I Human Immunodeficiency Virus Typed Particle Production in Presence of an Active Viral Protease,”J. Virol., 1996, pp. 6820-6725, vol. 70.
Charneau, et al., “A Second Origin of DNA Plus-Strand Synthesis Is Required for Optimal Human Immunodeficiency Virus Replication,” 1992, pp. 2814-2820, vol. 66.
Charneau, et al., “HIV-1 Reverse Transcription: A Termination Step at the Center of the Genome,”J. Mol. Biol., 1994, pp. 651-662 , vol. 241.
Cohen, et al., “Human Immunodeficiency Virus vpr Product Is a Virion-Associated Regulatory Protein,”J. Virol., 1990, pp. 3097-3099, vol. 64.
Cohen, et al., “Identification of HIV-1 vpr Product and Function,”J. Acq. Immune Def. Synd.,1990, pp. 11-18, vol. 13.
Dedera, et al., “Viral Protein R of Human Immunodeficiency Virus Types 1 and 2 Is Dispensable for Replication and Cytopathogenicity in Lymphoid Cells,”J. Virol., 1989, pp. 3205-3208, vol. 63.
Derosiers, “HIV with Multiple Gene Deletions as a Live Attenuated Vaccine for AIDS,”AIDS Research and Human Retroviruses, 1992, pp. 441-421, vol. 8.
Di Marzio, et al., “Mutational Analysis of Cell Cycle Arrest, Nuclear Localization, and Virion Packaging of Human Immunodeficiency Virus Type 1 Vpr,”J. Virol., 1995, pp. 7909-7916, vol. 69.
Dull, et al., “A Third-Generation Lentivirus Vector with a Conditional Packaging System,”J. Virol., 1998, pp. 8463-8471, vol. 72.
Engelman, et al., “Multiple Effects of Mutations in Human Immunodeficiency Virus Type 1 Interase on Viral Replication,”J. Virol., 1995, pp. 2729-2736, vol. 69.
Finer, et al., “kat: A High-Efficiency Retroviral Transduction System for Primary Human T Lymphocytes,”Blood, 1994, pp. 43-50, vol. 83.
Fletcher, T.M, III, et al., “Complementation of Integrase Function in HIV-1 Virons,”The EMBO Journal, 1997, pp. 5123-5138, vol. 16(16).
Fletcher, T.M. III, et al., “Complementation of Integrase Function in HIV-1 Virons,” Fourth Conference on Retroviruses and Opportunistic Infections, Jan. 22, 1997, Abstract No. 394.
Fletcher, T.M. III, et al., “Complementation of Integrase Functon in HIV-1 Virons,” Third Conference on Retroviruses and Opportunistic Infections, Jan. 28, 1996.
George, et al., “Current Methods in Sequence Comparison and Analysis,”Macromolecule Sequencing and Synthesis, Selected Methods and Applicationspp. 127-149.
Gibbs, et al., Construction and In Vitro Properties of SIV MAC Mutants with Deletions in “Nonessential”Genes AIDS Research and Human Retroviruses, 1994, pp. 607-616 vol. 10.
Gottlinger, et al., “Effect of Mutations Affecting the p6 Gag Protein on Human Immunodeficiency Virus Particle Release,”Proc. Natl. Acad. Sci., 1991, pp. 3195-3199, vol. 88.
Guyader, et al., “VPX Mutants Of HIV-2 Are Infectious in Established Cell Lines But Display A Severe Defect In Peripheral Blood Lymphocytes,”EMBO Journal, 1989, pp. 1169-1175, vol. 8(4).
Hattori, et al., “The HIV-2 Vpr Gene is Essential for Macrophage Infections,” p. 309 (Abstract).
Hattori, et al., “The Human Immunodeficiency Virus Type 2 vpr Gene is Essential for Productive Infection of Human Macrophages,”Proc. Natl.Acad. Sci. USA, 1990, pp. 8080-8084, vol. 87.
He, et al., “Human Immunodeficiency Virus Type 1 Viral Protein R (Vpr) Arrests Cells in theG2 Phase of the Cell Cycle by Inhibiting p34cdc2 Activity,”J. Virol., 1995, pp. 6705-6711, vol. 69(11).
Heinzinger, et al., “The Vpr Protein Of Human Immunodeficiency Virus Type 1 Influences Nuclear Localization Of Viral Nucleic Acids In Nondividing Host Cells,”Proc. Natl. Acad. Sci. USA,:1994, pp. 7311-7315, vol. 91.
Hoch, et al., “The Vpr Deletion Mutant of Simian Immunodeficiency Virus Induces AIDS in Rhesus Monkeys,”J Virol. 1995, pp. 4807-4813, vol. 69(8).
Horton, et al., “HIV-2 Viral Protein X Association with Gagp27 Capsid Protein,”Virology, 1994, pp. 453-457, vol. 199.
Hu, et al., Mutational Analysis of the Murine IDS-Defective Viral Genome Reveals a High Reversion Rate in Vivo and a Requirement for an Intact Pr60faf Protein for Efficient Induction of Disease,Journal of Virology, 1995, pp. 60-68.
Huang, et al., “Mutational Analysis of the Murine AIDS-Defective Viral Genome Reveals a High Reversion Rate In Vivo and a Requirement for an Intact Pr60gag Protein for Efficient Induction of Disease,”J. Virol., 1995, pp. 60-68.
Huang, et al., “P6Gag Is Required for Particle Production from Full-Length Human Immunodeficiency Virus Type 1 Molecular Clones Expressing Protease,”J. Virol., 1995, pp. 6810-6818.
Hutchinson, et al., “Utagenesis at a Specific Position in a DNA Sequence,”J. Biol. Chem. p. 6551, vol. 253.
Kafri, et al., “Sustained Expression of Genes Delivered Directly into Liver and Muscle by Lentiviral Vectors
Kappes John C.
Wu Xiaoyun
Bradley Arant Boult & Cummings LLP
Hara Eileen B O
LandOfFree
Trans-lentiviral vector particles and transduction of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Trans-lentiviral vector particles and transduction of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Trans-lentiviral vector particles and transduction of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4107289